Treatment of MM patients’ (N = 3; relapsed/refractory) BMMC with single agent anti-PD1, anti-OX40, or anti-GITR triggered a significant (*p < 0.05) expansion of Treg. This evidence concerns the gene TNFRSF18 and Miyoshi myopathy.